100 Bayer Road
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
477 articles with Bayer
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
In July 2017, Bayer launched a three-year, Phase III ASTEROID clinical trial of vilaprisan in patients with symptomatic uterine fibroids, with the intention of recruiting more than 3,600 patients in 900 sites in 40 countries.
Bayer Presents Five-Year Outcomes Data from the PROTECT VIII Extension Study at the 60th American Society of Hematology Annual Meeting
Study finds long-term safety and efficacy in subset of 33 hemophilia A patients who received treatment with Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) for five years was consistent with previous data analysis
Following successful evaluation, Bayer has chosen the GenoMAGIC™ platform to support its advanced molecular breeding program in several key crops
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the repo...
Bayer Pledges 5 Million Hands-On Science Learning Experiments for Children in the United States by 2025
New Pledge Accelerates 20+ Year Commitment to Improving Science Education; Program Kicks Off with Unveiling of "Science Studio" Alexa Skill
A class action, Dembrowski v. Bayer Inc., QBG 1611 of 2009, commenced in the Court of Queen’s Bench for Saskatchewan, was certified to advance claims regarding the combination oral contraceptives Yasmin® and Yaz® that Bayer marketed in Canada.
Bayer will cut 12,000 jobs as it prepares an overhaul of its business that includes exiting its animal health business as it deals with the fallout from its $63 billion acquisition of Monsanto. Additionally, the company said it will sell its 60 percent stake in Germany-based site services provide...
Bayer announced today that seven abstracts from its Hemophilia portfolio and development pipeline have been accepted for presentation during Scientific Sessions at the 2018 American Society of Hematology (ASH) Annual Meeting, December 1 – December 4, in San Diego, CA.
US Bioservices Selected by Bayer and Its Collaboration Partner Loxo Oncology, Inc. to Dispense Vitrakvi® (larotrectinib)
New therapy approved to treat gene fusions across several different types of tumors
Bayer U.S. today announced the appointments of Albert J. Mitchell and Michael Parrish to two of the company's corporate affairs leadership positions.
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
First treatment with a tumor-agnostic indication at the time of initial FDA approval
Bayer to give $120,000 through new Grants Fur Families program benefitting domestic violence survivors and their pets
Grant program raises awareness of the role pets play for survivors - helping to increase the number of domestic violence shelters offering on-site pet facilities
The U.S. Food and Drug Administration (FDA) gave the green light late Monday to Bayer oncology drug Vitrakvi, a first-of-its-kind TRK inhibitor, after late-stage clinical trial results showed a 75 percent overall response rate and 22 percent complete response rate across various solid tumors.
Cyclica Drives Drug Discovery Through AI-Augmented Integrated Network of Cloud-Based Technologies together with Bayer
Cyclica (www.cyclicarx.com), a Bayer G4A company is pleased to announce a collaboration with Bayer to advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies.
Increased Consumer Risks from Purchasing Erectile Dysfunction Medicine on the Gray Market Exposed in New Research
Bayer and the National Consumers League release white paper that explores the risks consumers face when purchasing erectile dysfunction (ED) medicines from illegal online pharmacies and provides policy recommendations for increasing safe access to ED medicines.
Launch Commenced; First-Time Generic Launch of Levitra®.
Genpact and Bayer to Co-innovate to Leverage Artificial Intelligence Capabilities for Patient Safety
Genpact today announced it has signed a multi-year agreement with Bayer.
A prostate cancer drug jointly developed by healthcare giant Bayer and Finland-based Orion can slow the spread of the disease, according to late-stage study results announced early Wednesday.
Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint
The safety and tolerability observed in the trial were consistent with previously published data on darolutamide.